Top Markets
#1 Cortex Cortex +174.22%
#2 GEKKO GEKKO +44.25%
#3 ADO Protocol ADO Protocol +18.41%
#4 o1.exchange o1.exchange +10.98%
#5 Official Trump Official Trump +10.62%
#6 aelf aelf +10.25%
#7 DAPPOS DAPPOS +9.52%
#8 Bless Bless +8.43%
#9 Status Status +7.95%
#10 Seeker Seeker +7.66%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Rank in Stocks #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Share Price
$59.98
Last synced: 2024-12-13
Market Cap
$1.22B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Longboard Pharmaceuticals, Inc. (LBPH)

Category

Healthcare
Revenue for Longboard Pharmaceuticals, Inc. (LBPH)
Revenue in Sep 2024 TTM: $8.00K
According to Longboard Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $8.00K. In 2022 the company made a revenue of 0.00 equal to the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Longboard Pharmaceuticals, Inc. from 2020 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $8.00K 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 157,803,650.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 75,265,991.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 196,803,989.28%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 27,849,900.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH